Skip to content

Treatment in Patients Hospitalized With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Treatment in Patients Hospitalized With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02219360
Acronym
TripAE
Enrollment
400
Registered
2014-08-18
Start date
2014-08-31
Completion date
2015-09-30
Last updated
2014-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

acute, exacerbation, chronic obstructive pulmonary disease

Brief summary

Chronic obstructive pulmonary disease has become a serious global health care and public health problems due to its high prevalence, high morbidity and heavy economic burden. Acute exacerbation of chronic obstructive pulmonary disease is one of the most important causes of death in patients with COPD. Systemic corticosteroids therapy is recommended in COPD exacerbations. In clinical practice for the treatment of acute exacerbation of COPD, antibiotic application is still controversial. Evidence from current guideline is based on strict criteria from randomized controlled trials, thus the given condition is simplified. Patients meet the criteria account for the minority in the real world. Therefore, it is still not clear whether most patients benefit from the recommended treatment. In our design, hospitalized patients with acute exacerbation of COPD will be enrolled, with their treatment, arterial hypoxemia, recovery time and length of hospitalization being observed. The main purpose is to evaluate the benefit effect of current recommended treatment of acute exacerbation of COPD in the real world.

Detailed description

Chronic obstructive pulmonary disease has become a serious global health care and public health problems due to its high prevalence, high morbidity and heavy economic burden. Acute exacerbation of COPD is one of the most important causes of death in patients with COPD. The global strategy for the diagnosis, management, and prevention of COPD recommends systemic corticosteroids therapy in COPD exacerbations as it can shorten recovery time, reduce treatment failure, improve lung function and arterial hypoxemia. In clinical practice for the treatment of acute exacerbation of COPD, antibiotic application is still controversial. Evidence from current guideline is based on strict criteria from randomized controlled trials, thus the given condition is simplified. Patients meet the criteria account for the minority in the real world. Therefore, it is still not clear whether most patients benefit from the recommended treatment. In our design, hospitalized patients with acute exacerbation of COPD will be enrolled, with their treatment, arterial hypoxemia, recovery time and length of hospitalization being observed. The main purpose is to evaluate the benefit effect of current recommended treatment of acute exacerbation of COPD in the real world.

Interventions

None listed

Sponsors

Beijing Chao Yang Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease * Age≥ 40years old

Exclusion criteria

* The first diagnosis which caused hospitalization is not acute exacerbation of chronic obstructive pulmonary disease * Chest radiography shows congestive heart failure * Chest CT shows lung cancer, active pulmonary tuberculosis, pulmonary thromboembolism or interstitial lung diseases * Serious cardiac failure, renal insufficiency or hepatic dysfunction

Design outcomes

Primary

MeasureTime frame
change of the score of COPD Assesment Test as a measurement of the overall condition of the patientbaseline, 1 month after dischahge, 2 months after discharge

Secondary

MeasureTime frame
change of the score of modified Medical British Research Council questionaire as a measurement of the overall condition of the patientbaseline, 1 month after discharge, 2 months after discharge

Other

MeasureTime frame
percentage of use of systemic corticosteroid in patients8 months after the first enrollment

Contacts

Primary ContactHuang Kewu, M.D.
kewuhuang@126.com86-10-85231167
Backup ContactWang Ying, Master
kokosalaki1020@gmail.com86-0-13426121753

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026